Difference between revisions of "Part:BBa K4593002:Design"
Line 16: | Line 16: | ||
===References=== | ===References=== | ||
+ | Lee, Chanyoung, et al. “Development of Advanced Chimeric Endolysin to Control Multidrug-Resistant Staphylococcus Aureus through Domain Shuffling.” ACS Infectious Diseases, vol. 7, no. 8, 28 May 2021, pp. 2081–2092. | ||
+ | https://doi.org/10.1021/acsinfecdis.0c00812. |
Revision as of 00:30, 27 September 2023
ClyC
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 681
Illegal AgeI site found at 550 - 1000COMPATIBLE WITH RFC[1000]
Design Notes
N/A
Source
Hybrid endolysin from domains of 12 natural staphylococcal endolysins.
References
Lee, Chanyoung, et al. “Development of Advanced Chimeric Endolysin to Control Multidrug-Resistant Staphylococcus Aureus through Domain Shuffling.” ACS Infectious Diseases, vol. 7, no. 8, 28 May 2021, pp. 2081–2092. https://doi.org/10.1021/acsinfecdis.0c00812.